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Introduction
Ductal pancreatic adenocarcinoma, the most frequent
malignancy of the pancreas, is characterized by retro-
peritoneal and perineural infiltration, early formation
of multiple metastases, and resistance to most of the
treatment regimens currently available. Handling the
aggressive growth of this disease represents a complex
and challenging task for both conservative and opera-
tive medicine [13]. Surgical resection, the patient’s
only hope for cure, offers a significantly improved
prognosis, with a median survival after resection of
1420 months and up to 25% 5-year survival rates
[1,4,5]. This is underlined by studies showing a
distinct advantage of potentially curative (R0) versus
palliative (R1/R2) surgery [1,3,5,6]. Furthermore,
when surgical resection was compared with radio-
chemotherapy for resectable pancreatic cancer, pa-
tients in the operative group fared significantly better,
with a median survival of 17 months versus 11 months
in the chemoradiation group [7]. However, the
median survival of patients with unresectable pan-
creatic cancer is around 48 months [5]. The few
improvements seen in these patients, especially with
regard to quality of life, are primarily due to the use of
gemcitabine as first-line chemotherapy [8].
The standard operation for tumors of the pancrea-
tic head is the pancreaticoduodenectomy (Whipple
procedure, mostly pylorus-preserving), whereas tu-
mors of the body or tail can be resected using a distal
pancreatectomy. Adjuvant chemotherapy has also
proven advantageous in terms of prolonging overall
survival, whereas neoadjuvant treatment regimens
and adjuvant radiochemotherapy are still considered
controversial, with large randomized controlled trials
(RCTs) required for further evaluation [9]. Further
concentration of the case load in tertiary care centers
[10], which can provide experienced diagnostic and
therapeutic measurements together with novel tar-
geted therapies in a translational research approach,
will hopefully further improve the outcomes of
patients with this devastating disease.
Principles of surgical treatment for pancreatic
cancer
The pancreaticoduodenectomy (KauschWhipple
procedure)
Walter Kausch and Allan Whipple pioneered pan-
creatic surgery in the 1910s by developing the
pancreaticoduodenectomy (PD) [11,12]. For a long
time, this technically demanding procedure was
associated with high morbidity and mortality and a
poor long-term outcome, leading people in the 1970s
and 1980s to question whether it should be performed
at all [4,13,14]. However, remarkable advances have
been made in (peri)operative management and espe-
cially in the surgical techniques used in the operation,
with various modifications such as vascular resections,
multi-visceral operations and extended lymphade-
nectomy, and PD has become the standard operative
procedure for tumors of the pancreatic head.
The pancreaticoduodenectomy is divided into three
parts: exploration, resection, and reconstruction of
the gastrointestinal continuity. After examination of
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the peritoneal cavity and the liver for metastatic
disease, a wide Kocher maneuver is performed to
examine the retroperitoneum and the superior me-
senteric artery (SMA) for potential tumor infiltration.
Following the gastrocolic venous trunk distally, the
superior mesenteric vein (SMV) is localized and a
tunnel is dissected between the neck of the pancreas
anteriorly and the SMV-portal vein trunk posteriorly,
while at the same time the portal vein is exposed at the
superior part of the pancreas. The gallbladder and the
common bile duct are then removed, and a transec-
tion is performed 1 cm from the tumor at the neck of
the pancreas. The (distal) stomach and duodenum are
dissected, enabling complete removal of the speci-
men.
Pylorus-preserving pancreaticoduodenectomy (PPPD)
Complications seen following partial resections of
the stomach with the KauschWhipple procedure,
such as gastric dumping syndromes, gastritis, and
ulcerations due to bile reflux, led to the introduc-
tion of a pylorus-preserving modification of the
classical PD. Introduced by Kenneth Watson in
the 1940s, the pylorus-preserving pancreaticoduo-
denectomy (PPPD) was not frequently used until
Traverso and Longmire re-introduced it in the late
1970s [1517]. Many researchers questioned
whether the PPPD was sufficiently radical, and
supporters of the procedure were called upon to
prove its usefulness. Some retrospective studies
showed benefits with regard to digestive function
and quality of life for the PPPD, whereas no
survival disadvantages or advantages were found by
other trials, either retrospective or prospective
randomized [1826]. Eventually, many studies
showed that there are no differences in postopera-
tive rates of delayed gastric emptying (DGE)
between PD and PPPD, although DGE had been
cited as a disadvantage of PPPD before [18,23,27
32].
Both classic and pylorus-preserving pancreatico-
duodenectomy are thus recommended for periampul-
lary tumors, with the classic procedure rather being
preferred in patients with large tumors, especially in
the dorsal part of the pancreatic head. For both
operations, a wide variety of techniques for the
management of the pancreatico-enteric anastomosis
have been described. The success of these techniques
depends more on the accuracy of the surgeon than on
the technique itself [33]. Large series were not able to
show superiority of any of the techniques, such as
pancreaticojejunostomy (end-to-side or end-to-end,
duct-to-mucosa or dunking) or pancreaticogastrost-
omy, as long as tension-free adaptation and tissue
perfusion together without distal obstruction are
ensured [3436]. However, occlusion of the pancrea-
tic duct by any material has been abandoned due to
unacceptably high complication (fistula) rates [37
39]. For re-establishment of gastrointestinal continu-
ity, a variety of techniques may be performed, such
as retrocolic reconstruction with a single limb for all
anastomoses, antecolic [28,40] or infracolic recon-
structions [41,42], but there is no definitive evidence
in favor of any one of them.
Resection for tumors of the body and the tail of the
pancreas
Fewer resections are performed for tumors of the
body and the tail of the pancreas than for pancreatic
head tumors. This is because tumors of the body and
tail, which have fewer clinical symptoms, tend to be
diagnosed later [43,44]. Usually, a distal pancreatect-
omy is performed for these tumors, and includes
dissection of peripancreatic lymph nodes and poten-
tially the spleen, with transection of the pancreas to
the left of the SMV-PV trunk and ligation of the
pancreatic duct, followed by suturing the stump or
lately a complete transection with a stapler device
[45,46]. Although distal pancreatectomies have higher
pancreatic fistula rates than pancreaticoduodenec-
tomies, this does not present a major clinical challenge
because the fistulas usually heal with external drai-
nage [34]. Splenic preservation may also be accom-
plished without compromising the oncologic
radicality, complication rates, operative time, and
length of postoperative stay [47,48]. Moreover, there
are fewer infectious complications when performing
splenic preservation for distal pancreatectomies [49].
Total pancreatectomy
Total pancreatectomy is a combination of pancreati-
coduodenectomy and distal pancreatectomy together
with a local lymphadenectomy. It is reserved for
patients with multilocular or large tumors of the
pancreas. However, because the procedure is accom-
panied by postoperative exocrine and endocrine
insufficiency, and is associated with the highest
mortality rates for all pancreatic surgeries, it is rarely
used for pancreatic resective surgery [34].
Value of extended lymphadenectomy
Extended lymphadenectomy was developed as a result
of the observation that lymph nodes of the para-aortic
region were frequently positive for pancreatic cancer
metastases. Some retrospective studies from Japan in
the 1980s showed a survival benefit for extended
lymphadenectomy in pancreaticoduodenectomy.
However, three RCTs, as well as a large Japanese
RCT published in abstract form, showed no increase
in survival rates for the extended procedure but a
trend toward increased morbidity [26,5052]. Several
factors, including ambiguous definition of extended/
radical resection, differences in the number of re-
sected lymph nodes, and different adjuvant treatment
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regimens, do not allow comparison of these studies.
Furthermore, a feasibility analysis for a potential RCT
for lymphadenectomy in pancreatic cancer showed
that (even if one considers these estimations as not
exact) the number of patients needed for such a study
would be far too high for the study ever to be
performed [53]. Thus, extended lymphadenectomy
cannot be recommended, and should only be con-
sidered when patients are included in a RCT.
Vascular resections
A report by Fuhrman et al. suggests that venous
infiltration is due to the localization rather than the
grade of the tumor, and that it does not necessarily have
to be a contraindication for resectability [54]. Portal
venous resection has been intensively examined in
clinical trials [55]. Interestingly, large series show
comparable short- and long-term outcomes for PD
with venous resection [5659]. However, the definition
of resectability in the case of venous infiltration is still
controversial [6063]. Reconstruction of PVand SMV
after a CattellBrash maneuver is usually possible
without generating tension on the venous anastomosis,
which may also be prevented by using a venous graft.
Arterial resection
Arterial resection is usually reserved for advanced
tumors which also infiltrate the retroperitoneal neural
plexus and which are associated with a poor prog-
nosis. Because the procedure is technically challen-
ging, few studies have addressed the question of
whether to perform arterial resection in patients
undergoing pancreaticoduodenectomy [6466].
These studies reveal that arterial resection is feasible.
However, data on the benefit of arterial resection are
limited, and therefore it should only be conducted in
the context of adequately powered RCTs.
Quality of life after pancreatic cancer resection
Huang et al. reported on the quality of life and
outcomes for patients with pancreatic cancer who
Table I. Survival data of pancreatic cancer patients.
References Time
period
Additional
treatment
Number of
patients
Survival median
(months)
5-year
survival
Capussotti et al.
(2003) [71]
19881998 No adjuvant chemotherapy 100 8.4%
Carpelan-Holmstro¨m et al.
(2005) [4]
19901996 Not documented 10 0.2%
Mosca et al. (1997) No adjuvant chemotherapy 221 9.6%
Neoptolemos et al.
(2004) [9]
19942000 No adjuvant treatment 69 16.9 11%
Chemoradiation treatment 73 13.9 7%
Chemotherapy 75 21.6 29%
Chemoradiation
treatment/chemotherapy
72 19.9 13%
Richter et al. (2003) [6] 19721998 No adjuvant chemotherapy 194 25.4%
Schmidt et al. (2004) [72] 19802002 No adjuvant chemotherapy 202
Tran et al. (2004) [6,70] 19922000 Chemoradiation treatment (9) 47 PPPD 12 16%
Chemoradiation treatment (10) 43 SW 11 16%
Wagner et al. (2004) [5] 19932001 ESPAC-1 trial 211 19.8%
PPPD, pylorus-preserving pancreaticoduodenectomy; SW, standard Whipple procedure.
Table II. Mortality and morbidity after pancreatic head resections in pancreatic cancer.
References Time period Number of patients Mortality Morbidity
Bu¨chler et al. (2003) [34] 19932001 468 SW/ PPPD 1.3% 36%
Capussotti et al. (2003) [71] 19881998 149 Whipple procedures 5.4% (60 days) 37.5%
Mosca et al. (1997) [23] SW 34.4%
PPPD 45.8%
Richter et al. (2003) [6] 19721998 194 SW 3.09% 29.9%
Seiler et al. (2005) [69] 19962001 66 SW 3% 68.2%
64 PPPD 2% 54.7%
Tran et al. (2004) [70] 19922000 83 SW 7% (30 days)
87 PPPD 3% (30 days)
Wagner et al. (2004) [5] 19932001 78 SW 52%
87 PPPD 40%
PPPD, pylorus-preserving pancreaticoduodenectomy; SW, standard Whipple procedure.
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undergo pancreaticoduodenectomy compared to pa-
tients who undergo laparoscopic cholecystectomy
[67]. Patients who undergo pancreaticoduodenect-
omy suffer significantly more frequently from weight
loss and symptoms related to endocrine and exocrine
insufficiency than patients who undergo laparoscopic
cholecystectomy. Normal physical activity was re-
ported in 92% of patients undergoing duodenopan-
createctomy [67]. Wenger et al. performed a RCT to
evaluate the quality of life after two different pancrea-
tic head resection techniques: the classic and the
pylorus-preserving pancreaticoduodenectomy. Using
the EORTC-QLQ-30 questionnaire, they found bet-
ter gastrointestinal function and better weight gain in
the pylorus-preserving group [68].
Survival (Tables IIII)
Survival is prolonged after curative resection and is
better in lymph node negative patients [5]. Wagner
et al., in a study of 211 pancreatic cancer patients
following resection (PD, PPPD, classical Whipple, left
resection, and total pancreatectomy), showed a 5-year
survival rate of 4.3% after R2 and R1 resection,
compared with 24.2% in patients in whom an R0
resection was performed [5]. Similar findings were
reported by Seiler et al. [69], who showed in a RCT
that median survival depends on the resection margin
(R0 versus R1) and is similar in patients who undergo
pancreaticoduodenectomy and PPPD. In R0 resected
patients, the median survival was 28 months with
pancreaticoduodenectomy and 26 months with
PPPD. The median survival was 9 months in R/
resected pancreaticoduodenectomy patients and 16
months in the PPPD patients, revealing no statistical
difference [69].
Survival after pancreatic cancer resection is depen-
dent on the lymph node status: when there are no
metastases to peripancreatic lymph nodes and when
the resection margins are tumor-free, survival is
increased. Five-year survival rates of 7.5% in lymph
node positive patients and up to 29% in lymph node
negative patients have been documented [5,6,52,70].
Moreover, vascular and perineural infiltration are also
associated with shortened survival [5].
Palliative resection
In pancreatic cancer surgery, R0 resection should be
attempted, whenever possible. Despite preoperative
determination of resectability, true R0 resections are
not easily accomplished. For tumors of the pancreatic
body and head, resectability can be estimated when
the pancreas is transected above the portal/superior
mesenteric vein, but at this stage the resection has to
be completed even if an R0 resection cannot be
achieved.
In a recent study, the median survival in patients
with a positive resection margin was 11 months; when
these patients were subdivided into R1 and R2
resection, survival analysis revealed a median survival
of 9.8 months for R2 resected patients and 15 months
for R1 resected patients [5]. These data clearly
underline that if tumor resection is performed, as
much tumor tissue as possible has to be removed [5].
Conclusion
Surgery for pancreatic cancer can be performed with
low morbidity and mortality rates at specialized high-
volume tertiary centers. Technical differences in
managing both the resective and reconstructive parts
of the operation are dependent on the surgeon’s
preference rather than on actual evidence-based
guidelines. The criteria determining resectability, the
advantages and disadvantages of venous or arterial
resections, and to some extent the radicality of the
lymph node dissection are still discussed with some
controversy.
Improved (neo)adjuvant treatment, together with
targeted therapies and earlier diagnosis in a transla-
tional basic clinical research approach, are likely to
improve the dismal prognosis of pancreatic cancer
patients in the future. However, all these new ther-
apeutic possibilities have to be evaluated in controlled
clinical trials with adequate statistical power.
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